

# PRV

PATENT- OCH REGISTRERINGSVERKET  
Patentavdelningen

10/534 191  
Rec'd PCTO 06 MAY 2005

#2

SE/03) 1712

## Intyg Certificate

Härmed intygas att bifogade kopior överensstämmer med de handlingar som ursprungligen ingivits till Patent- och registreringsverket i nedannämnda ansökan.

Ansökan ingavs ursprungligen på engelska.

This is to certify that the annexed is a true copy of the documents as originally filed with the Patent- and Registration Office in connection with the following patent application.

The application was originally filed in English.

(71) Sökande AstraZeneca AB, Södertälje SE  
Applicant (s)

(21) Patentansökningsnummer 0203304-1  
Patent application number

(86) Ingivningsdatum 2002-11-07  
Date of filing

REC'D 18 NOV 2003

WIPO

PCT

Stockholm, 2003-11-11

För Patent- och registreringsverket  
For the Patent- and Registration Office

*Sonia André*

Sonia André

Avgift  
Fee

## PRIORITY DOCUMENT

SUBMITTED OR TRANSMITTED IN  
COMPLIANCE WITH RULE 17.1(a) OR (b)

PATENT- OCH  
REGISTRERINGSVERKET  
SWEDEN

Postadress/Adress  
Box 5055  
S-102 42 STOCKHOLM

Telefon/Phone  
+46 8 782 25 00  
Vx 08-782 25 00

Telex  
17978  
PATOREG S

Telefax  
+46 8 666 02 86  
08-666 02 86

## NOVEL COMPOUNDS

### Field of the Invention

5 The present invention relates to novel arylthiazolythioalkylamine derivatives, processes for their preparation, compositions containing them and their use in therapy.

### Background of the Invention


10 Nitric oxide is produced in mammalian cells from L-arginine by the action of specific nitric oxide synthases (NOSs). These enzymes fall into two distinct classes - constitutive NOS (cNOS) and inducible NOS (iNOS). At the present time, two constitutive NOSs and one inducible NOS have been identified. Of the constitutive NOSs, an endothelial enzyme (ecNOS) is involved with smooth muscle relaxation and the regulation of blood pressure  
15 and blood flow, whereas the neuronal enzyme (ncNOS) serves as a neurotransmitter and appears to be involved in the regulation of various biological functions such as cerebral ischaemia. Inducible NOS has been particularly implicated in the pathogenesis of inflammatory diseases. Regulation of these enzymes should therefore offer considerable potential in the treatment of a wide variety of disease states (J. E. Macdonald, *Ann. Rep. Med. Chem.*, 1996, 31, 221 - 230).  
20

Considerable effort has been expended in efforts to identify compounds that act as specific inhibitors of one or more isoforms of the enzyme nitric oxide synthase. The use of such compounds in therapy has also been widely claimed.

25 Patent application PCT/SE02/00876 discloses certain arylheteroalkylamine derivatives that are useful as NOS inhibitors. It has now been found that certain compounds that are within the generic scope of this application, but which are not specifically exemplified therein, possess surprisingly advantageous properties. These compounds are the subject of the  
30 present application.

Disclosure of the invention

According to the present invention, there is provided a compound of formula (I)



wherein:

T and W independently represent CR<sup>1</sup> or N; and when more than one R<sup>1</sup> group is present, each may be selected independently;

X and R<sup>1</sup> independently represent H, C1 to 4 alkyl, C1 to 4 alkoxy, halogen, CN, C≡CH, NO<sub>2</sub>, CHO, COCH<sub>3</sub> or NHCHO; said alkyl or alkoxy group being optionally further substituted by one or more fluorine atoms;

Y represents C1 to 4 alkyl, C1 to 4 alkoxy, halogen, CN, C≡CH, NO<sub>2</sub>, CHO, COCH<sub>3</sub> or NHCHO; said alkyl or alkoxy group being optionally further substituted by one or more fluorine atoms;

or a pharmaceutically acceptable salt, enantiomer or racemate thereof.

In one embodiment, Y represents CN or halogen.

The compounds of formula (I) and their pharmaceutically acceptable salts, enantiomers and racemates have the advantage that they are inhibitors of the enzyme nitric oxide synthase (NOS). In particular, the compounds of formula (I) and their pharmaceutically acceptable salts, enantiomers and racemates have the advantage that they are inhibitors of the inducible isoform of the enzyme nitric oxide synthase (iNOS).

The invention further provides a process for the preparation of compounds of formula (I) or a pharmaceutically acceptable salt, enantiomer or racemate thereof.

5 According to the invention there is also provided a compound of formula (I), or a pharmaceutically acceptable salt, enantiomer or racemate thereof, for use as a medicament.

Another aspect of the invention provides the use of a compound of formula (I) or a pharmaceutically acceptable salt, enantiomer or racemate thereof, in the manufacture of a  
10 medicament, for the treatment or prophylaxis of diseases or conditions in which inhibition of nitric oxide synthase activity is beneficial.

A more particular aspect of the invention provides the use of a compound of formula (I) or a pharmaceutically acceptable salt, enantiomer or racemate thereof, in the manufacture of a  
15 medicament, for the treatment or prophylaxis of inflammatory disease.

According to the invention, there is also provided a method of treating, or reducing the risk of, diseases or conditions in which inhibition of nitric oxide synthase activity is beneficial which comprises administering to a person suffering from or at risk of, said disease or  
20 condition, a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt, enantiomer or racemate thereof.

More particularly, there is also provided a method of treating, or reducing the risk of, inflammatory disease in a person suffering from or at risk of, said disease, wherein the  
25 method comprises administering to the person a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt, enantiomer or racemate thereof.

The compounds of the present invention may also be used advantageously in combination  
30 with a second pharmaceutically active substance; particularly in combination with a cyclooxygenase inhibitor; more particularly in combination with a selective inhibitor of the inducible isoform of cyclooxygenase (COX-2). Thus, in a further aspect of the invention

there is provided the use of a compound of formula (I) or a pharmaceutically acceptable salt, enantiomer or racemate thereof, in combination with a COX-2 inhibitor for the treatment of inflammation, inflammatory disease and inflammatory related disorders. And there is also provided a method of treating, or reducing the risk of, inflammation, inflammatory disease and inflammatory related disorders in a person suffering from or at risk of, said disease or condition, wherein the method comprises administering to the person a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt, enantiomer or racemate thereof in combination with a COX-2 inhibitor.

10

Particular compounds of the invention include:

2-[[[(1*R*,3*S*)-3-amino-4-hydroxy-1-(5-thiazolyl)butyl]thio]-5-chloro-3-pyridinecarbonitrile;

2-[[[(1*R*,3*S*)-3-amino-4-hydroxy-1-(5-thiazolyl)butyl]thio]-4-chloro-benzonitrile;

(2*S*,4*R*)-2-amino-4-[[2-chloro-5-(trifluoromethyl)phenyl]thio]-5-thiazolebutanol;

15 2-[[[(1*R*,3*S*)-3-amino-4-hydroxy-1-(5-thiazolyl)butyl]thio]-6-(trifluoromethyl)-3-pyridinecarbonitrile;

2-[[[(1*R*,3*S*)-3-amino-4-hydroxy-1-(5-thiazolyl)butyl]thio]-5-chloro-benzonitrile;

and pharmaceutically acceptable salts, enantiomers or racemates thereof.

20 Unless otherwise indicated, the term "C1 to 4 alkyl" referred to herein denotes a straight or branched chain alkyl group having from 1 to 4 carbon atoms. Examples of such groups include methyl, ethyl, n-propyl, i-propyl, n-butyl, i-butyl and t-butyl.

25 Unless otherwise indicated, the term "C1 to 4 alkoxy" referred to herein denotes a straight or branched chain alkoxy group having from 1 to 4 carbon atoms. Examples of such groups include methoxy, ethoxy, n-propoxy, i-propoxy and t-butoxy.

Unless otherwise indicated, the term "halogen" referred to herein denotes fluoro, chloro, bromo and iodo.


30

Examples of a "C1 to 4 alkyl or C1 to 4 alkoxy optionally further substituted by one or more fluorine atoms" include  $\text{CH}_2\text{F}$ ,  $\text{CHF}_2$ ,  $\text{CF}_3$ ,  $\text{CF}_3\text{CF}_2$ ,  $\text{CF}_3\text{CH}_2$ ,  $\text{CH}_2\text{FCH}_2$ ,  $\text{CH}_3\text{CF}_2$ ,  $\text{CF}_3\text{CH}_2\text{CH}_2$ ,  $\text{OCF}_3$  and  $\text{OCH}_2\text{CF}_3$ .

- 5 According to the invention, we further provide a process for the preparation of compounds of formula (I), or a pharmaceutically acceptable salt, enantiomer or racemate thereof which comprises:


(a) reaction of a compound of formula (II)

10



(II)

wherein T, X, Y and W are as defined in formula (I) and L<sup>1</sup> represents a leaving group, with a compound of formula (III)




(III)

15

or


(b) reaction of a compound of formula (IV)

20



(IV)

wherein T, W, X and Y are as defined in formula (I),  
with a compound of formula (V)



(V)

wherein  $L^2$  is a leaving group;

and where desired or necessary converting the resultant compound of formula (I), or another salt thereof, into a pharmaceutically acceptable salt thereof; or converting one compound of formula (I) into another compound of formula (I); and where desired converting the resultant compound of formula (I) into an optical isomer thereof.

In process (a), the reaction is performed by treating a nucleophile of formula (III) with an electrophile of formula (II) in an inert solvent. Suitable leaving groups  $L^1$  include sulphonates and halides, particularly fluoride or chloride. The reaction is generally performed in the presence of a non-nucleophilic base such as sodium hydride or caesium carbonate. Suitable organic solvents are those such as N,N-dimethylformamide, N-methyl-2-pyrrolidinone, tetrahydrofuran and dimethylsulfoxide. The reaction is generally conducted at a temperature between 0 °C and the boiling point of the solvent.

In process (b), the reactants (IV) and (V) are coupled together in a suitable inert solvent such as tetrahydrofuran using, for example, Mitsunobu conditions. Thus, for example, the reactants are treated with a phosphine derivative and an azo derivative at a suitable temperature, generally between 0 °C and the boiling point of the solvent. Suitable


phosphine derivatives include triphenylphosphine and tributylphosphine. Suitable azo derivatives include diethyl azodicarboxylate, diisopropyl azodicarboxylate and 1,1'-(azodicarbonyl)dipiperidine. Suitable leaving groups  $L^2$  include hydroxy.

- 5 Alternatively in process (b), the reaction is performed by treating a nucleophile of formula (IV) with an electrophile of formula (V) in an inert solvent. Suitable leaving groups  $L^2$  include sulphonates and halides, particularly chloride or bromide. The reaction is generally performed in the presence of a non-nucleophilic base such as sodium hydride or caesium carbonate. Suitable organic solvents are those such as N,N-dimethylformamide, 10 N-methyl-2-pyrrolidinone, tetrahydrofuran and dimethylsulfoxide. The reaction is generally conducted at a temperature between 0 °C and the boiling point of the solvent.

It will be apparent to a person skilled in the art that in the above processes it may be desirable or necessary to protect an amine or hydroxyl or other potentially reactive group. 15 Suitable protecting groups and details of processes for adding and removing such groups may be found by reference to the standard text "Protective Groups in Organic Synthesis", 3rd Edition (1999) by Greene and Wuts.

In one preferred embodiment, amine groups are protected as carbamate derivatives, for 20 example, as t-butyloxycarbamates.

In another particularly preferred embodiment, the amine and hydroxyl groups of compounds of formula (I) are protected simultaneously as a cyclic hemi-aminal as in formula (VI).



(VI)



Specific examples of the use of protecting groups are given in the Examples section.

The present invention includes compounds of formula (I) in the form of salts, in particular acid addition salts. Suitable salts include those formed with both organic and inorganic acids. Such acid addition salts will normally be pharmaceutically acceptable although salts of non-pharmaceutically acceptable acids may be of utility in the preparation and purification of the compound in question. Thus, preferred salts include those formed from hydrochloric, hydrobromic, sulphuric, phosphoric, citric, tartaric, lactic, pyruvic, acetic, succinic, fumaric, maleic, methanesulphonic and benzenesulphonic acids.

Salts of compounds of formula (I) may be formed by reacting the free base, or a salt, enantiomer or racemate thereof, with one or more equivalents of the appropriate acid. The reaction may be carried out in a solvent or medium in which the salt is insoluble or in a solvent in which the salt is soluble, for example, water, dioxane, ethanol, tetrahydrofuran or diethyl ether, or a mixture of solvents, which may be removed *in vacuo* or by freeze drying. The reaction may also be a metathetical process or it may be carried out on an ion exchange resin.

Intermediate compounds may be used as such or in protected form. Protecting groups and details of processes for their removal may be found by reference to the standard text "Protective Groups in Organic Synthesis", 3rd Edition (1999) by Greene and Wuts.

The compounds of the invention and intermediates thereto may be isolated from their reaction mixtures and, if necessary further purified, by using standard techniques.

The compounds of formula I may exist in enantiomeric forms. Therefore, all enantiomers, diastereomers, racemates and mixtures thereof are included within the scope of the invention. The various optical isomers may be isolated by separation of a racemic mixture of the compounds using conventional techniques, for example, fractional crystallisation, or HPLC.

Intermediate compounds may also exist in enantiomeric forms and may be used as purified enantiomers, diastereomers, racemates or mixtures.

The compounds of formula (I), and their pharmaceutically acceptable salts, enantiomers and racemates, are useful because they possess pharmacological activity in animals. In particular, the compounds are active as inhibitors of the enzyme nitric oxide synthase. More particularly, they are inhibitors of the inducible isoform of the enzyme nitric oxide synthase and as such are predicted to be useful in therapy, for example, as anti-inflammatory agents. They may also have utility as inhibitors of the neuronal isoform of the enzyme nitric oxide synthase.

The compounds and their pharmaceutically acceptable salts, enantiomers and racemates are indicated for use in the treatment or prophylaxis of diseases or conditions in which synthesis or oversynthesis of nitric oxide synthase forms a contributory part. In particular, the compounds are indicated for use in the treatment of inflammatory conditions in mammals including man.

Conditions that may be specifically mentioned are:

osteoarthritis, rheumatoid arthritis, rheumatoid spondylitis, gouty arthritis and other arthritic conditions, inflamed joints;

eczema, psoriasis, dermatitis or other inflammatory skin conditions such as sunburn;

inflammatory eye conditions including uveitis, glaucoma and conjunctivitis;

lung disorders in which inflammation is involved, for example, asthma, bronchitis, chronic obstructive pulmonary disease, pigeon fancier's disease, farmer's lung, acute respiratory distress syndrome;

bacteraemia, endotoxaemia (septic shock), aphthous ulcers, gingivitis, pyresis, pain, meningitis and pancreatitis;

conditions of the gastrointestinal tract including inflammatory bowel disease, Crohn's disease, atrophic gastritis, gastritis varioliforme, ulcerative colitis, coeliac disease, regional ileitis, peptic ulceration, irritable bowel syndrome, reflux oesophagitis, damage to the gastrointestinal tract resulting from infections by, for example, *Helicobacter pylori*, or from treatments with non-steroidal anti-inflammatory drugs;

and other conditions associated with inflammation.

The compounds will also be useful in the treatment and alleviation of acute pain or persistent inflammatory pain or neuropathic pain or pain of a central origin.

- 5 We are particularly interested in the conditions inflammatory bowel disease, rheumatoid arthritis, osteoarthritis, chronic obstructive pulmonary disease and pain.

The compounds of formula (I) and their pharmaceutically acceptable salts, enantiomers and racemates may also be useful in the treatment or prophylaxis of diseases or conditions in  
10 addition to those mentioned above. For example, the compounds may be useful in the treatment of atherosclerosis, cystic fibrosis, hypotension associated with septic and/or toxic shock, in the treatment of dysfunction of the immune system, as an adjuvant to short-term immunosuppression in organ transplant therapy, in the control of onset of diabetes, in the maintenance of pancreatic function in diabetes, in the treatment of vascular complications  
15 associated with diabetes and in co-therapy with cytokines, for example TNF or interleukins.

The compounds of formula (I) may also be useful in the treatment of hypoxia, for example in cases of cardiac arrest and stroke, neurodegenerative disorders including nerve degeneration and/or nerve necrosis in disorders such as ischaemia, hypoxia, hypoglycaemia, epilepsy, and  
20 in external wounds (such as spinal cord and head injury), hyperbaric oxygen convulsions and toxicity, dementia, for example pre-senile dementia, Alzheimer's disease and AIDS-related dementia, Sydenham's chorea, Parkinson's disease, Tourette's syndrome, Huntington's disease, amyotrophic lateral sclerosis, multiple sclerosis, muscular dystrophy, Korsakoff's disease, imbecility relating to a cerebral vessel disorder, sleeping disorders, schizophrenia, depression,  
25 pain, autism, seasonal affective disorder, jet-lag, depression or other symptoms associated with premenstrual syndrome (PMS), anxiety and septic shock. Compounds of formula (I) may also be expected to show activity in the prevention and reversal of drug addiction or tolerance such as tolerance to opiates and diazepines, treatment of drug addiction, treatment of migraine and other vascular headaches, neurogenic inflammation, in the treatment of  
30 gastrointestinal motility disorders, cancer and in the induction of labour.

We are particularly interested in the conditions stroke, Alzheimer's disease, Parkinson's disease, multiple sclerosis, schizophrenia, migraine, cancer, septic shock and pain.

Prophylaxis is expected to be particularly relevant to the treatment of persons who have  
5 suffered a previous episode of, or are otherwise considered to be at increased risk of, the disease or condition in question. Persons at risk of developing a particular disease or condition generally include those having a family history of the disease or condition, or those who have been identified by genetic testing or screening to be particularly susceptible to developing the disease or condition.

10

For the above mentioned therapeutic indications, the dosage administered will, of course, vary with the compound employed, the mode of administration and the treatment desired. However, in general, satisfactory results are obtained when the compounds are administered at a dosage of the solid form of between 1 mg and 2000 mg per day.

15

The compounds of formula (I), and pharmaceutically acceptable derivatives thereof, may be used on their own, or in the form of appropriate pharmaceutical compositions in which the compound or derivative is in admixture with a pharmaceutically acceptable adjuvant, diluent or carrier. Administration may be by, but is not limited to, enteral (including oral,  
20 sublingual or rectal), intranasal, inhalation, intravenous, topical or other parenteral routes. Conventional procedures for the selection and preparation of suitable pharmaceutical formulations are described in, for example, "Pharmaceuticals - The Science of Dosage Form Designs", M. E. Aulton, Churchill Livingstone, 1988. The pharmaceutical composition preferably comprises less than 80% and more preferably less than 50% of a  
25 compound of formula (I), or a pharmaceutically acceptable salt, enantiomer or racemate thereof.

According to the invention, we further provide a pharmaceutical composition comprising a compound of formula (I), or a pharmaceutically acceptable salt, enantiomer or racemate  
30 thereof, in admixture with a pharmaceutically acceptable adjuvant, diluent or carrier.

There is also provided a process for the preparation of such a pharmaceutical composition which comprises mixing the ingredients.

The compounds of formula (I), and pharmaceutically acceptable derivatives thereof, may also be advantageously used in combination with a COX inhibitor, more particularly in combination with a COX-2 inhibitor. Particularly preferred COX-2 inhibitors are Celecoxib and MK-966. The NOS inhibitor and the COX-2 inhibitor may either be formulated together within the same pharmaceutical composition for administration in a single dosage unit, or each component may be individually formulated such that separate dosages may be administered either simultaneously or sequentially.

The invention is illustrated, but in no way limited, by the following examples:

The following abbreviations are used:- DMSO (dimethylsulfoxide), DMF (*N,N*-dimethylformamide), THF (tetrahydrofuran), NMP (*N*-methylpyrrolidinone).

#### Example 1

2-[[[(1*R*,3*S*)-3-Amino-4-hydroxy-1-(5-thiazolyl)butyl]thio]-5-chloro-3-pyridinecarbonitrile ethanedioate

a) (4*S*)-4-[(2*R*)-2-Hydroxy-2-(2-chloro-5-thiazolyl)ethyl]-2,2-dimethyl-3-oxazolidinecarboxylic acid, 1,1-dimethylethyl ester and (4*S*)-4-[(2*S*)-2-hydroxy-2-(2-chloro-5-thiazolyl)ethyl]-2,2-dimethyl-3-oxazolidinecarboxylic acid, 1,1-dimethylethyl ester

*n*-Butyl lithium (2.0M in hexanes, 21.6 ml) was added dropwise to a solution of 2-chlorothiazole (5.4 g) in THF (400 ml) at -78 °C under a nitrogen atmosphere. After 15 minutes a solution of (4*S*)-2,2-dimethyl-4-(2-oxoethyl)-3-oxazolidinecarboxylic acid, 1,1-dimethylethyl ester (7.0 g) in THF (140 ml) was added dropwise and the reaction mixture was stirred for a further 60 minutes. The cooling was then removed and the mixture was stirred at room temperature for 60 minutes. The reaction mixture was poured

into saturated aqueous ammonium chloride and the products extracted with diethyl ether. The combined extracts were washed with brine, dried (magnesium sulfate), filtered and evaporated. Purification by chromatography (silica, 20% ethyl acetate/isohexane as eluent) gave the (4*S*, 2*S*) sub-title compound (5.2 g) as a colourless oil.

5 MS APCI +ve  $m/z$  363  $[(M+H)^+]$ .

$^1H$  NMR 400MHz (DMSO- $d_6$ , 90°C) 7.49 (1H, s), 5.69 (1H, d), 4.85 (1H, dd), 3.96-3.86 (2H, m), 3.84-3.77 (1H, m), 2.10-1.99 (1H, m), 1.90 (1H, dt), 1.47 (3H, s), 1.40 (12H, s).

Further elution gave the (4*S*, 2*R*) sub-title compound (5.1 g, 42%) as a colourless oil.

10 MS APCI +ve  $m/z$  363  $[(M+H)^+]$ .

$^1H$  NMR 400MHz (DMSO- $d_6$ , 90°C) 7.49 (1H, s), 5.70 (1H, d), 4.92 (1H, apparent quin.), 4.05-3.98 (1H, m), 3.91-3.84 (2H, m), 2.16-2.07 (1H, m), 1.84 (1H, ddd), 1.48 (3H, s), 1.41 (12H, s).

15 b) (4*S*)-4-[(2*S*)-2-Hydroxy-2-(5-thiazolyl)ethyl]-2,2-dimethyl-3-oxazolidinecarboxylic acid, 1,1-dimethylethyl ester

10% Palladium on charcoal was added to a solution of the (4*S*, 2*S*) product from Example 1 step (a) (5.2 g) and sodium acetate (2.9 g) in methanol (120 ml). The reaction mixture was stirred at 50 °C under 5 atmospheres of hydrogen for 16 h. The mixture was filtered and evaporated. The residue was then dissolved in dichloromethane, re-filtered and evaporated to give the sub-title compound (4.8 g) as a colourless oil.

MS APCI +ve  $m/z$  329  $[(M+H)^+]$ .

20  $^1H$  NMR 400MHz (DMSO- $d_6$ , 90°C) 8.90 (1H, d), 7.73 (1H, d), 5.49 (1H, d), 4.94 (1H, dt), 3.93-3.91 (2H, m), 3.85-3.78 (1H, m), 2.09 (1H, ddd), 1.94-1.89 (1H, m), 1.47 (3H, s), 1.41 (3H, s), 1.40 (9H, s).

25 c) (4*S*)-4-[(2*R*)-2-(Benzoylthio)-2-(5-thiazolyl)ethyl]-2,2-dimethyl-3-oxazolidinecarboxylic acid, 1,1-dimethylethyl ester

To a solution of triphenylphosphine (7.9 g) in dry THF (100 ml) at 0 °C was added diisopropylazodicarboxylate (5.9 ml) dropwise over 5 minutes. After the addition was complete the mixture was stirred for 20 minutes and then a solution of the product from Example 1 step (b) (4.8 g) and thiobenzoic acid (3.5 ml) in THF (50 ml) was added. The

cooling bath was removed and stirring continued at room temperature overnight. The mixture was concentrated and the residue was purified by chromatography (silica, 10% diethyl ether/*isohexane* as eluent) to give the sub-title compound (4.4 g) as a yellow solid. MS APCI +ve  $m/z$  449 ( $[M+H]^+$ ).

5

d) (4S)-4-[(2R)-2-[(5-chloro-3-cyano-2-pyridinyl)thio]-2-(5-thiazolyl)ethyl]-2,2-dimethyl-3-oxazolidinecarboxylic acid, 1,1-dimethylethyl ester

The product from Example 1 step (c) (290 mg) was treated with 7M ammonia in methanol (5 ml) and stirred at room temperature for 6 h. The solvent was evaporated, the residue  
10 dissolved in dry DMF (5 ml) and treated with 2,5-dichloro-3-pyridinecarbonitrile (112 mg) followed by cesium carbonate (210 mg) under nitrogen. The reaction mixture was stirred for 18 h, poured into brine and ethyl acetate and the organic layer separated, washed with water (2 x), brine and dried (magnesium sulfate). The solvent was evaporated and the residue purified by chromatography (silica, 25% ethyl acetate/dichloromethane as eluent)  
15 to give the sub-title compound (160 mg) as a viscous oil. MS APCI +ve  $m/z$  481 ( $[M+H]^+$ ).

e) 2-[(1R,3S)-3-Amino-4-hydroxy-1-(5-thiazolyl)butyl]thio]-5-chloro-3-pyridinecarbonitrile ethanedioate

20 The product from Example 1 step (d) (160 mg) was stirred in 4M HCl in dioxane (1 ml) and methanol (1 ml) for 1 h. The reaction mixture was evaporated, azeotroped with diethyl ether (3 x), then treated with 1 equivalent of oxalic acid in ethanol (10 ml). The clear solution was treated with diethyl ether until complete precipitation and the solid collected by filtration, washed with diethyl ether and dried *in vacuo* at 40 °C for 2 h to give the title  
25 compound (60 mg) as a light brown solid. MS APCI + ve  $m/z$  341 ( $[M+H]^+$ ).

$^1H$  NMR 400MHz (DMSO- $d_6$ ) 9.07 (1H, s), 8.87 (1H, d), 8.56 (1H, d), 8.07 (2H, bs), 8.00 (1H, s), 5.71 (1H, t), 3.57 (1H, dd), 3.49 (1H, dd), 3.12-3.04 (1H, m), 2.45-2.32 (2H, m).

30

Example 2

2-[[[(1R,3S)-3-Amino-4-hydroxy-1-(5-thiazolyl)butyl]thio]-4-chloro-benzonitrile  
dihydrochloride

a) (4S)-4-[(2R)-2-[(5-Chloro-2-cyanophenyl)thio]-2-(5-thiazolyl)ethyl]-2,2-dimethyl-3-oxazolidinecarboxylic acid, 1,1-dimethylethyl ester

The product from Example 1 step (c) (290 mg) was treated with 2-fluoro-4-chlorobenzonitrile (101 mg) and cesium carbonate (211 mg) according to the procedure of Example 1 step (d) to give the sub-title compound (160 mg) as a viscous oil.  
MS APCI +ve  $m/z$  480 ( $[M+H]^+$ ).

b) 2-[[[(1R,3S)-3-Amino-4-hydroxy-1-(5-thiazolyl)butyl]thio]-4-chloro-benzonitrile  
dihydrochloride

The product of Example 2 step (a) was stirred in 4M HCl in dioxane (1 ml) and methanol (1 ml) for 1 h. The reaction mixture was evaporated, azeotroped with diethyl ether (3 x) and dried *in vacuo* at 40 °C for 2 h to give the title compound (113 mg) as a pale yellow solid.

MS APCI + ve  $m/z$  340 ( $[M+H]^+$ ).

$^1H$  NMR 400MHz (DMSO- $d_6$ ) 9.05 (1H, s), 8.15 (2H, bs), 7.86 (1H, d), 7.83 (1H, s), 7.81 (1H, d), 7.55 (1H, dd), 5.57 (1H, t), 3.59 (1H, dd), 3.51 (1H, dd), 3.07 (1H, br s), 2.31-2.23 (2H, m).

Example 3

(2S,4R)-2-Amino-4-[[2-chloro-5-(trifluoromethyl)phenyl]thio]-5-thiazolebutanol  
hydrochloride

a) (4S)-4-[(2R)-2-[[2-Chloro-5-(trifluoromethyl)phenyl]thio]-2-(5-thiazolyl)ethyl]-2,2-dimethyl-3-oxazolidinecarboxylic acid, 1,1-dimethylethyl ester

The product from Example 1 step (c) (190 mg) was treated with 4-chloro-3-fluorobenzotrifluoride (83 mg) and cesium carbonate (163 mg) according to the procedure of Example 1 step (d) to give the sub-title compound (105 mg) as a viscous oil.  
MS APCI +ve  $m/z$  523 ( $[M+H]^+$ ).



b) (2*S*,4*R*)-2-Amino-4-[[2-chloro-5-(trifluoromethyl)phenyl]thio]-5-thiazolebutanol hydrochloride

The product of Example 3 step (a) was reacted according to the procedure of Example 2 step (b) to give the title compound (58 mg) as a white solid containing the (2*S*, 4*S*) diastereomer as a 30% impurity.

MS APCI + ve  $m/z$  383 ( $[M+H]^+$ ).

$^1H$  NMR 300MHz (DMSO- $d_6$ ) 9.04 (1H, s), 8.15 (2H, br s), 7.86 (1H, d), 7.77-7.69 (2H, m), 7.61 (1H, s), 5.54 (1H, t), 3.63-3.55 (1H, m), 3.13-3.01 (2H, m), 2.34-2.19 (2H, m).

Example 4

2-[[[(1*R*,3*S*)-3-Amino-4-hydroxy-1-(5-thiazolyl)butyl]thio]-6-(trifluoromethyl)-3-pyridinecarbonitrile dihydrochloride

a) (4*S*)-4-[(2*R*)-2-[[3-Cyano-6-(trifluoromethyl)-2-pyridinyl]thio]-2-(5-thiazolyl)ethyl]-2,2-dimethyl-3-oxazolidinecarboxylic acid, 1,1-dimethylethyl ester

The product from Example 1 step (c) (190 mg) was treated with 2-chloro-6-trifluoromethyl-3-pyridinecarbonitrile (86 mg) and cesium carbonate (163 mg) according to the procedure of Example 1 step (d) to give the sub-title compound (117 mg) as a viscous oil.

MS APCI +ve  $m/z$  (515  $[M+H]^+$ ).

b) 2-[[[(1*R*,3*S*)-3-Amino-4-hydroxy-1-(5-thiazolyl)butyl]thio]-6-(trifluoromethyl)-3-pyridinecarbonitrile dihydrochloride

The product of Example 4 step (a) was reacted according to the procedure of Example 2 step (b) to give the title compound (85 mg) as a white solid.

MS APCI + ve  $m/z$  (375  $[M+H]^+$ ).

$^1H$  NMR 300MHz (DMSO- $d_6$ ) 9.04 (1H, s), 8.57 (1H, d), 8.20 (2H, bs), 7.97 (1H, s), 7.89 (1H, d), 5.68 (1H, t), 3.60-3.56 (1H, m), 3.52 (1H, dd), 3.18-3.09 (1H, m), 2.48-2.41 (2H, m).

Example 52-[[[(1R,3S)-3-Amino-4-hydroxy-1-(5-thiazolyl)butyl]thio]-5-chloro-benzonitrile dihydrochloridea) (4S)-4-[(2R)-2-[(4-Chloro-2-cyanophenyl)thio]-2-(5-thiazolyl)ethyl]-2,2-dimethyl-3-oxazolidinecarboxylic acid, 1,1-dimethylethyl ester

The product from Example 1 step (c) (190 mg) was treated with 5-chloro-2-fluorobenzonitrile (65 mg) and cesium carbonate (163 mg) according to the procedure of Example 1 step (d) to give the sub-title compound (160 mg) as a viscous oil.

MS APCI +ve  $m/z$  480 ( $[M+H]^+$ ).

b) 2-[[[(1R,3S)-3-Amino-4-hydroxy-1-(5-thiazolyl)butyl]thio]-5-chloro-benzonitrile dihydrochloride

The product of Example 5 step (a) was reacted according to the procedure of Example 2 step (b) to give the title compound (97 mg) as a pale yellow solid.

MS APCI + ve  $m/z$  340 ( $[M+H]^+$ ).

$^1H$  NMR 300MHz (DMSO  $d_6$ ) 9.04 (1H, s), 8.27 (2H, br s), 8.04 (1H, d), 7.81 (1H, s), 7.77-7.74 (2H, m), 5.58 (1H, t), 3.57 (1H, dd), 3.51 (1H, dd), 3.07-3.00 (1H, m), 2.27 (2H, t).

Screens

The pharmacological activity of compounds according to the invention was tested in the following screens.

Screen 1

The activity of compounds of formula (I), or a pharmaceutically acceptable salt, enantiomer or racemate thereof, may be screened for nitric oxide synthase inhibiting activity by a procedure based on that of Förstermann *et al.*, Eur. J. Pharm., 1992, 225, 161-165. Nitric

oxide synthase converts  $^3\text{H}$ -L-arginine into  $^3\text{H}$ -L-citrulline which can be separated by cation exchange chromatography and quantified by liquid scintillation counting.

Enzyme is prepared, after induction, from the cultured murine macrophage cell line J774A-1 (obtained from the laboratories of the Imperial Cancer Research Fund). J774A-1 cells are cultured in Dulbeccos Modified Eagles Medium (DMEM) supplemented with 10% foetal bovine serum, 4 mM L-glutamine and antibiotics (100 units/ml penicillin G, 100 mg/ml streptomycin & 0.25 mg/ml amphotericin B). Cells are routinely grown in 225 cm<sup>3</sup> flasks containing 35 ml medium kept at 37 °C and in a humidified atmosphere containing 5% CO<sub>2</sub>.

Nitric oxide synthase is produced by cells in response to interferon- $\gamma$  (IFN $\gamma$ ) and lipopolysaccharide (LPS). The medium from confluent culture flasks is removed and replaced with 25 ml (per flask) of fresh medium containing 1 mg/ml LPS and 10 units/ml IFN $\gamma$ . After a period of 17-20 hours in culture, harvesting of cells is accomplished by scraping the cell sheet from the flask surface into the culture medium. Cells are collected by centrifugation (1000 g for 10 minutes) and lysate prepared by adding to the cell pellet a solution containing 50 mM Tris-HCl (pH 7.5 at 20 °C), 10% (v/v) glycerol, 0.1% (v/v) Triton-X-100, 0.1 mM dithiothreitol and a cocktail of protease inhibitors comprising leupeptin (2 mg/ml), soya bean trypsin inhibitor (10 mg/ml), aprotinin (5 mg/ml) and phenylmethylsulphonyl fluoride (50 mg/ml).

For the assay, 25  $\mu\text{l}$  of substrate cocktail (50 mM Tris-HCl (pH 7.5 at 20 °C), 400  $\mu\text{M}$  NADPH, 20  $\mu\text{M}$  flavin adenine dinucleotide, 20  $\mu\text{M}$  flavin mononucleotide, 4  $\mu\text{M}$  tetrahydrobiopterin, 12  $\mu\text{M}$  L-arginine and 0.025 mCi L-[ $^3\text{H}$ ] arginine) is added to wells of a 96 well filter plate (0.45 $\mu\text{m}$  pore size) containing 25  $\mu\text{l}$  of a solution of test compound in 50 mM Tris-HCl. The reaction is started by adding 50  $\mu\text{l}$  of cell lysate (prepared as above) and after incubation for 1 hour at room temperature is terminated by addition of 50  $\mu\text{l}$  of an aqueous solution of 3 mM nitroarginine and 21 mM EDTA.

Labelled L-citrulline is separated from labelled L-arginine using Dowex AG-50W. 150  $\mu\text{l}$  of a 25% aqueous slurry of Dowex 50W (Na<sup>+</sup> form) is added to the assay after which the whole

is filtered into 96 well plates. 75  $\mu$ l of filtrate is sampled and added to wells of 96 well plates containing solid scintillant. After allowing the samples to dry the L-citrulline is quantified by scintillation counting.

- 5 In a typical experiment basal activity is 300 dpm per 75  $\mu$ l sample which is increased to 1900 dpm in the reagent controls. Compound activity is expressed as  $IC_{50}$  (the concentration of drug substance which gives 50% enzyme inhibition in the assay) and aminoguanidine, which gives an  $IC_{50}$  (50% inhibitory concentration) of 10  $\mu$ M, is tested as a standard to verify the procedure. Compounds are tested at a range of concentrations and from the inhibitions  
10 obtained  $IC_{50}$  values are calculated. Compounds that inhibit the enzyme by at least 25% at 100  $\mu$ M are classed as being active and are subjected to at least one retest.

In the above screen, the compounds of Examples 1 to 5 were tested and gave  $IC_{50}$  values of less than 10  $\mu$ M indicating that they are expected to show useful therapeutic activity.

15

## Screen 2

- Recombinant human NO synthases (iNOS, eNOS & nNOS) were expressed in *E. coli* and lysates were prepared in Hepes buffer (pH 7.4) containing co-factors (FAD, FMN, H<sub>4</sub>B),  
20 protease inhibitors, lysozyme and the detergent, CHAPS. These preparations were used, at suitable dilution, to assess inhibition of the various isoforms. Inhibition of NOS was determined by measuring the formation of L-[<sup>3</sup>H]citrulline from L-[<sup>3</sup>H]arginine using an adaptation of the method of Förstermann *et al.*<sup>9</sup> Enzyme assays were performed in the presence of 3  $\mu$ M [<sup>3</sup>H]arginine, 1 mM NADPH and other co-factors required to support  
25 NOS activity (FAD, FMN, H<sub>4</sub>B, calmodulin, Ca<sup>2+</sup>). Since various NOS inhibitors have been reported to exhibit slow binding kinetics, or to inactivate the enzyme in a time dependent manner, enzyme and inhibitor were pre-incubated for 60 min in the presence of NADPH before addition of arginine to initiate the reaction. Incubations continued for a further 60 min before the assays were quenched and [<sup>3</sup>H]citrulline separated from  
30 unreacted substrate by chromatography on Dowex-50W resin in a 96-well format.

In the above screen, the compounds of Examples 1 to 5 were tested and gave  $IC_{50}$  values of less than 10  $\mu M$  against the iNOS enzyme indicating that they are expected to show useful therapeutic activity.

5 Screen 3

Compounds also show activity against the human form of induced nitric oxide synthase as can be demonstrated in the following assay.

10 The human colorectal carcinoma cell line, DLD-1 (obtained from the European Collection of Animal Cell Culture - cell line number 90102540) was routinely grown in RPMI 1640 supplemented with 10%(v/v) foetal bovine serum, and 2mM L-glutamine, at 37 °C in 5% CO<sub>2</sub>.


15 Nitric oxide synthase was induced in cells by addition of medium containing human recombinant gamma-IFN (1000 units/ml), TNF-alpha (200 U/ml), IL-6 (200 U/ml) and IL-1-beta (250 U/ml). After incubation for 18 hours at 37 °C, the medium was removed and the cells washed with warm phosphate buffered saline. Cells were incubated for a further 5 hours at 37 °C / 5% CO<sub>2</sub> in RPMI 1640 containing 100 $\mu M$  L-arginine and 100 $\mu M$  verapamil-HCl in the presence and absence of test compounds.

20 Nitrite accumulation was determined by mixing an equal volume of culture media with Griess reagent (10 mg/ml sulphanilamide, 1 mg *N*-(1-naphthyl)ethylenediamine in 1 ml 2.5% (v/v) phosphoric acid). Inhibition in the presence of compounds was calculated relative to the nitrite levels produced by untreated cells.  $IC_{50}$  values were estimated from a semi-log plot of % inhibition versus concentration of compound.

25 In this screen the compounds of Examples 1 to 5 gave  $IC_{50}$  values of less than 100  $\mu M$ , indicating that they are predicted to show useful therapeutic activity.

**CLAIMS:**

1. A compound of formula (I)



wherein:

T and W independently represent CR<sup>1</sup> or N; and when more than one R<sup>1</sup> group is present, each may be selected independently;

X and R<sup>1</sup> independently represent H, C1 to 4 alkyl, C1 to 4 alkoxy, halogen, CN, C≡CH, NO<sub>2</sub>, CHO, COCH<sub>3</sub> or NHCHO; said alkyl or alkoxy group being optionally further substituted by one or more fluorine atoms;

Y represents C1 to 4 alkyl, C1 to 4 alkoxy, halogen, CN, C≡CH, NO<sub>2</sub>, CHO, COCH<sub>3</sub> or NHCHO; said alkyl or alkoxy group being optionally further substituted by one or more fluorine atoms;  
or a pharmaceutically acceptable salt, enantiomer or racemate thereof.

2. A compound according to Claim 1 wherein Y represents CN or halogen.

3. A compound of formula (I), according to Claim 1, which is:

2-[[[(1R,3S)-3-amino-4-hydroxy-1-(5-thiazolyl)butyl]thio]-5-chloro-3-pyridinecarbonitrile;

2-[[[(1R,3S)-3-amino-4-hydroxy-1-(5-thiazolyl)butyl]thio]-4-chloro-benzonitrile;

(2S,4R)-2-amino-4-[[2-chloro-5-(trifluoromethyl)phenyl]thio]-5-thiazolebutanol;

2-[[[(1*R*,3*S*)-3-amino-4-hydroxy-1-(5-thiazolyl)butyl]thio]-6-(trifluoromethyl)-3-pyridinecarbonitrile;

2-[[[(1*R*,3*S*)-3-amino-4-hydroxy-1-(5-thiazolyl)butyl]thio]-5-chloro-benzonitrile;  
or a pharmaceutically acceptable salt, enantiomer or racemate thereof.

5

4. A compound of formula (I), according to any one of Claims 1 to 3, or a pharmaceutically acceptable salt, enantiomer or racemate thereof, for use as a medicament.

5. A pharmaceutical composition comprising a compound of formula (I) according to any  
10 one of Claims 1 to 3, or a pharmaceutically acceptable salt, enantiomer or racemate thereof, in admixture with a pharmaceutically acceptable adjuvant, diluent or carrier.

6. The use of a compound of formula (I) according to any one of Claims 1 to 3, or a pharmaceutically acceptable salt, enantiomer or racemate thereof, in the manufacture of a  
15 medicament for the treatment or prophylaxis of human diseases or conditions in which inhibition of nitric oxide synthase activity is beneficial.

7. The use as claimed in Claim 6 wherein it is predominantly inducible nitric oxide synthase that is inhibited.

20

8. The use of a compound of formula (I) as defined in any one of Claims 1 to 3, or a pharmaceutically acceptable salt, enantiomer or racemate thereof, in the manufacture of a medicament, for the treatment or prophylaxis of inflammatory diseases.

25

9. The use as claimed in Claim 8 wherein the disease is inflammatory bowel disease.

10. The use as claimed in Claim 8 wherein the disease is rheumatoid arthritis.


11. The use as claimed in Claim 8 wherein the disease is osteoarthritis.

30

12. The use of a compound of formula (I) as defined in any one of Claims 1 to 3, or a pharmaceutically acceptable salt, enantiomer or racemate thereof, in the manufacture of a medicament, for the treatment or prophylaxis of pain.
- 5 13. The use of a compound of formula (I) as defined in any one of Claims 1 to 3, or a pharmaceutically acceptable salt, enantiomer or racemate thereof, in combination with a COX-2 inhibitor, in the manufacture of a medicament, for the treatment or prophylaxis of inflammatory diseases.
- 10 14. A method of treating, or reducing the risk of, human diseases or conditions in which inhibition of nitric oxide synthase activity is beneficial which comprises administering a therapeutically effective amount of a compound of formula (I), as defined in any one of Claims 1 to 3, or a pharmaceutically acceptable salt, enantiomer or racemate thereof, to a person suffering from, or at increased risk of, such diseases or conditions.
- 15 15. A method of treatment according to Claim 14 in which it is predominantly inducible nitric oxide synthase that is inhibited.
- 20 16. A method of treating, or reducing the risk of, inflammatory disease in a person suffering from, or at risk of, said disease, wherein the method comprises administering to the person a therapeutically effective amount of a compound of formula (I), as defined in any one of Claims 1 to 3, or a pharmaceutically acceptable salt, enantiomer or racemate thereof.
- 25 17. A process for the preparation of a compound of formula (I), as defined in any one of Claims 1 to 3, or a pharmaceutically acceptable salt, enantiomer or racemate thereof, wherein the process comprises:
- (a) reaction of a compound of formula (II)




24



(II)


wherein T, X, Y and W are as defined in Claim 1 and L<sup>1</sup> represents a leaving group,  
with a compound of formula (III)



(III)


or

(b) reaction of a compound of formula (IV)



(IV)

wherein T, W, X and Y are as defined in Claim 1,  
with a compound of formula (V)



(V)

wherein L<sup>2</sup> is a leaving group;


and where desired or necessary converting the resultant compound of formula (I), or another salt thereof, into a pharmaceutically acceptable salt thereof; or converting one compound of formula (I) into another compound of formula (I); and where desired converting the resultant compound of formula (I) into an optical isomer thereof.

3

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65  
66  
67  
68  
69  
70  
71  
72  
73  
74  
75  
76  
77  
78  
79  
80  
81  
82  
83  
84  
85  
86  
87  
88  
89  
90  
91  
92  
93  
94  
95  
96  
97  
98  
99  
100  
101  
102  
103  
104  
105  
106  
107  
108  
109  
110  
111  
112  
113  
114  
115  
116  
117  
118  
119  
120  
121  
122  
123  
124  
125  
126  
127  
128  
129  
130  
131  
132  
133  
134  
135  
136  
137  
138  
139  
140  
141  
142  
143  
144  
145  
146  
147  
148  
149  
150  
151  
152  
153  
154  
155  
156  
157  
158  
159  
160  
161  
162  
163  
164  
165  
166  
167  
168  
169  
170  
171  
172  
173  
174  
175  
176  
177  
178  
179  
180  
181  
182  
183  
184  
185  
186  
187  
188  
189  
190  
191  
192  
193  
194  
195  
196  
197  
198  
199  
200  
201  
202  
203  
204  
205  
206  
207  
208  
209  
210  
211  
212  
213  
214  
215  
216  
217  
218  
219  
220  
221  
222  
223  
224  
225  
226  
227  
228  
229  
230  
231  
232  
233  
234  
235  
236  
237  
238  
239  
240  
241  
242  
243  
244  
245  
246  
247  
248  
249  
250  
251  
252  
253  
254  
255  
256  
257  
258  
259  
260  
261  
262  
263  
264  
265  
266  
267  
268  
269  
270  
271  
272  
273  
274  
275  
276  
277  
278  
279  
280  
281  
282  
283  
284  
285  
286  
287  
288  
289  
290  
291  
292  
293  
294  
295  
296  
297  
298  
299  
300  
301  
302  
303  
304  
305  
306  
307  
308  
309  
310  
311  
312  
313  
314  
315  
316  
317  
318  
319  
320  
321  
322  
323  
324  
325  
326  
327  
328  
329  
330  
331  
332  
333  
334  
335  
336  
337  
338  
339  
340  
341  
342  
343  
344  
345  
346  
347  
348  
349  
350  
351  
352  
353  
354  
355  
356  
357  
358  
359  
360  
361  
362  
363  
364  
365  
366  
367  
368  
369  
370  
371  
372  
373  
374  
375  
376  
377  
378  
379  
380  
381  
382  
383  
384  
385  
386  
387  
388  
389  
390  
391  
392  
393  
394  
395  
396  
397  
398  
399  
400  
401  
402  
403  
404  
405  
406  
407  
408  
409  
410  
411  
412  
413  
414  
415  
416  
417  
418  
419  
420  
421  
422  
423  
424  
425  
426  
427  
428  
429  
430  
431  
432  
433  
434  
435  
436  
437  
438  
439  
440  
441  
442  
443  
444  
445  
446  
447  
448  
449  
450  
451  
452  
453  
454  
455  
456  
457  
458  
459  
460  
461  
462  
463  
464  
465  
466  
467  
468  
469  
470  
471  
472  
473  
474  
475  
476  
477  
478  
479  
480  
481  
482  
483  
484  
485  
486  
487  
488  
489  
490  
491  
492  
493  
494  
495  
496  
497  
498  
499  
500  
501  
502  
503  
504  
505  
506  
507  
508  
509  
510  
511  
512  
513  
514  
515  
516  
517  
518  
519  
520  
521  
522  
523  
524  
525  
526  
527  
528  
529  
530  
531  
532  
533  
534  
535  
536  
537  
538  
539  
540  
541  
542  
543  
544  
545  
546  
547  
548  
549  
550  
551  
552  
553  
554  
555  
556  
557  
558  
559  
560  
561  
562  
563  
564  
565  
566  
567  
568  
569  
570  
571  
572  
573  
574  
575  
576  
577  
578  
579  
580  
581  
582  
583  
584  
585  
586  
587  
588  
589  
590  
591  
592  
593  
594  
595  
596  
597  
598  
599  
600  
601  
602  
603  
604  
605  
606  
607  
608  
609  
610  
611  
612  
613  
614  
615  
616  
617  
618  
619  
620  
621  
622  
623  
624  
625  
626  
627  
628  
629  
630  
631  
632  
633  
634  
635  
636  
637  
638  
639  
640  
641  
642  
643  
644  
645  
646  
647  
648  
649  
650  
651  
652  
653  
654  
655  
656  
657  
658  
659  
660  
661  
662  
663  
664  
665  
666  
667  
668  
669  
670  
671  
672  
673  
674  
675  
676  
677  
678  
679  
680  
681  
682  
683  
684  
685  
686  
687  
688  
689  
690  
691  
692  
693  
694  
695  
696  
697  
698  
699  
700  
701  
702  
703  
704  
705  
706  
707  
708  
709  
710  
711  
712  
713  
714  
715  
716  
717  
718  
719  
720  
721  
722  
723  
724  
725  
726  
727  
728  
729  
730  
731  
732  
733  
734  
735  
736  
737  
738  
739  
740  
741  
742  
743  
744  
745  
746  
747  
748  
749  
750  
751  
752  
753  
754  
755  
756  
757  
758  
759  
760  
761  
762  
763  
764  
765  
766  
767  
768  
769  
770  
771  
772  
773  
774  
775  
776  
777  
778  
779  
780  
781  
782  
783  
784  
785  
786  
787  
788  
789  
790  
791  
792  
793  
794  
795  
796  
797  
798  
799  
800  
801  
802  
803  
804  
805  
806  
807  
808  
809  
810  
811  
812  
813  
814  
815  
816  
817  
818  
819  
820  
821  
822  
823  
824  
825  
826  
827  
828  
829  
830  
831  
832  
833  
834  
835  
836  
837  
838  
839  
840  
84

Abstract

There are provided novel compounds of formula (I)



wherein T, X, Y and W are as defined in the specification, and pharmaceutically acceptable salts thereof, and enantiomers and racemates thereof; together with processes for their preparation, compositions containing them and their use in therapy. The compounds are inhibitors of nitric oxide synthase and are thereby particularly useful in the treatment or prophylaxis of inflammatory disease and pain.